Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.38 USD
-0.01 (-1.99%)
Updated May 10, 2024 03:57 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
PBLA 0.38 -0.01(-1.99%)
Will PBLA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PBLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PBLA
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
PBLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
Other News for PBLA
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Panbela Therapeutics announces issuance of new patent in US, Canada
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
Panbela Therapeutics announces delay of expected data from pancreatic cancer treatment trial